Location: Home > Pharma China Web Edition
  • search
  • go
  • Editor's Picks
  • 10/29/2024VCs Move to Launch U.S.-Based Companies to Advance Drugs Developed in ...
  • 10/24/2024Patent Term Extensions In China: Overviews And Takeaways (Mondaq)
  • 10/24/2024Reinventing Your China Strategy: A Podcast Preview of the China Health...
  • 10/24/2024U.S. and China Compete for Top Position in the Global Drug Development...
  • 10/21/2024Changing Chinese Market Dynamics Hit Merck Where It Hurts (SCRIP Citel...
  • 10/21/2024Clinical Benefit, Price, and Regulatory Approval of Cancer Drugs Grant...
  • 10/16/2024As U.S. Efforts Stall, China Pushes Ahead with CRISPR Treatments for M...
  • 10/16/2024Understanding the NewCo Model: A Trending Approach of Chinese Pharmace...
  • 10/16/2024China Biopharma Tracker – Q3 2024 (PharmaDJ)
  • 10/16/2024China's New Policies On Foreign Investment In Healthcare And Biotechno...
  • 10/8/2024NRDL China: 2024 Outlook (Simon Kucher)
  • 10/1/2024China's Pharmaceutical Antimonopoly Guidelines Pose New Challenges for...
  • 9/27/2024Pharma Companies in Beijing Free Trade Zone to Benefit from Relaxed Da...
  • 9/23/2024Is Biotech the Next Battleground in US-China Decoupling? (SCMP)
  • 9/20/2024Why 'Big Pharma' Will be the Next China Trade War Battleground (Invest...
  • 9/20/2024Another Twist in the Biosecure Drama Leaves Bill's Fate Uncertain
  • 9/19/2024China's Implementation of Patent Term Adjustment (SM)
  • 9/17/2024Biopharma Prepares to Pivot from China as Biosecure Act Advances (Phar...
  • 9/12/2024China Biopharma Tracker – August 2024 (PharmaDJ)
  • 9/12/2024Equity Investment + Licensing: The NewCo Model Paves a New Path for Ch...
  • 9/11/2024NewCo Model Gains Traction among Chinese Biotechs (ThePharmaLetter)
  • 9/11/2024China Boosts Regulatory Framework for Local Pharmaceutical Manufacturi...
  • 9/10/2024China Opens Doors to Foreign Investment in Cell Therapy and Wholly For...
  • 9/4/2024Report on Emerging Trends and Implications of Non-communicable Disease...
  • 9/4/2024Acceleration in China+1 trend in Pharmaceuticals Sector! (HDFC)
  • 8/30/2024Regional Price Differences of Medical Services: Evidence from China (B...
  • 8/29/2024Pharmaceutical Patent Disputes in China | The Nuances of "Offer to Sel...
  • 8/27/2024China Proposed New Anti-Monopoly Guidelines for the Pharmaceutical Sec...
  • 8/22/2024What Drives China's Healthcare Expenditure? A Theoretical and Empirica...
  • 8/22/2024InnoCare Pharma: A Sample of Accelerated Commercialization for Biotech...
  • Page:4/7 Total number of articles:182: [First][<<] [2] [3] [4] [5] [6] [>>] [End]
  • Site map | Contact Us | Links
  • © Wicon International Group